Sequana shares surge after FDA approval for alfapump
Sequana expects to launch the device, which is already approved in Europe, in the US in H2 2025.
Therapy Area
Mainz Biomed partners with Quest for colorectal cancer screening test
Vivani begins exenatide implant trial for obesity in Australia
FDA expands BiVACOR artificial heart study after successful first implants
Karmanos Cancer Institute commences prescription of liver cancer device
Hologic agrees with CDC to develop reagents for H5N1 bird flu testing
ClearNote and Southampton researchers partner for pancreatic cancer test study
KU ADRC partners with BYU for Alzheimer’s blood test study
